Why perform early ADME/Mass Balance analysis with Xceleron?
Human plasma profiles of new drug candidates are not accurately predicted by in vitro systems and preclinical species are not always representative. Reliable quantitative data for important circulating metabolites result only from a human radiolabel study. Radiolabel studies in humans and data on circulating metabolites are best obtained as soon as possible in clinical development before long-term preclinical studies commence. Traditional human radiolabel studies are expensive. When an early ADME study is performed, our clients can obtain a human metabolite profile early and very cost-effectively. Any decision before the human radiolabel study is made at risk and may need to be re-evaluated after radiolabel data is available.
